CEO Executive AssistantGene therapy biotechs are building at the frontier of medicine. AAV vector delivery, lentiviral constructs, base editing, prime editing, and RNA-based gene correction are transforming what is possible for patients with rare genetic diseases and beyond. For CEOs in this space, the technical complexity of the platform, the manufacturing intensity, and the novel regulatory environment create a distinctive delegation challenge.
Gene therapy CEOs are often scientific founders who have built deep expertise in vector biology, manufacturing, and clinical translation. This expertise is a genuine asset in external credibility. But the CEO who is reviewing vector titer data, attending manufacturing deviation investigations, or managing individual clinical site issues is not leading their company strategically. They are doing expensive technical labor.
This delegation framework addresses the specific organizational structure and accountability mechanisms that gene therapy biotech CEOs need to lead at scale.
The Gene Therapy Biotech Leadership Context
Gene therapy companies face distinctive operational challenges:
Vector manufacturing complexity: AAV, lentiviral, and other vector manufacturing processes are technically demanding, scale-intensive, and subject to significant process variability. Manufacturing failures can devastate clinical timelines and company value. This creates enormous pressure for CEO manufacturing oversight.
Novel regulatory environment: FDA and EMA are still developing regulatory frameworks for many gene therapy modalities. The regulatory strategy for a gene therapy product requires sophisticated agency engagement and is highly dependent on precedent development.
Rare disease focus: Many gene therapy programs address rare diseases with small patient populations, high unmet need, and demanding patient and family community expectations. Managing rare disease community relationships requires sensitivity and authenticity.
One-shot curative hypothesis: Gene therapies that may provide lifetime benefit from a single treatment face specific pricing, access, and outcomes evidence challenges that require early strategic attention.
Manufacturing access scarcity: CGMP manufacturing capacity for gene therapy vectors is scarce. Securing manufacturing access, whether through CDMOs or internal manufacturing buildout, requires strategic CEO-level decisions.
What Only the CEO Can Do
In a gene therapy biotech, the CEO’s non-delegable responsibilities include:
- Investor relations and major fundraising
- Strategic partnership and licensing discussions with large pharma and gene therapy-focused acquirers
- Board governance and investor reporting
- Manufacturing strategy decisions above a defined investment threshold
- Patient and rare disease community relationship building at the organizational level
- Senior leadership hiring and development
- FDA senior-level relationship management for novel regulatory pathway development
- Organizational strategy and platform prioritization
The Gene Therapy Leadership Team
Chief Scientific Officer: Owns the gene therapy platform, vector design, and preclinical research programs. Must have deep expertise in gene therapy biology and ideally established relationships with the leading academic gene therapy centers.
VP of Manufacturing or Chief Technical Officer: Owns all manufacturing operations, including vector production, quality control, manufacturing process development, and CDMO relationships. This is a critical role in gene therapy given manufacturing’s centrality to program success.
Chief Medical Officer: Owns clinical development strategy, clinical operations, and regulatory strategy for IND through BLA. Should have experience with gene therapy clinical programs or rare disease drug development.
VP of Regulatory Affairs: Owns regulatory strategy and FDA/EMA interactions, working closely with the CMO. Should have direct experience with gene therapy regulatory submissions.
VP of Quality: Owns GMP quality systems, batch release, and CGMP compliance. In gene therapy, quality failures are existential risks that require dedicated leadership.
CFO: Owns financial management, investor reporting infrastructure, and financial planning.
Business Development Director: Manages the partnership pipeline and coordinates CEO-level BD conversations.
Delegating Manufacturing Operations
Manufacturing is the most critical and most tempting area for gene therapy CEO over-involvement. A manufacturing failure, whether a batch loss, a contamination event, or a CDMO capacity issue, can set a program back months and materially affect company value. This creates a powerful motivation for CEO involvement.
But the answer to manufacturing risk is not CEO operational oversight; it is excellent manufacturing leadership with strong quality systems and clear escalation protocols.
Your VP of Manufacturing should own all manufacturing operations: batch production planning, CDMO relationship management, process development, and quality systems. You review manufacturing performance in monthly leadership team meetings covering batch success rates, critical quality attributes, and CDMO milestone achievement. You engage when manufacturing issues have strategic implications: a major batch failure that will delay a clinical milestone, a CDMO capacity shortfall that requires a strategic manufacturing decision, or a quality system finding with regulatory implications.
For guidance on how pharma and biotech CEOs delegate technical functions, see our pharma drug pipeline delegation guide.
Delegating Regulatory Strategy for Novel Pathways
Gene therapy regulatory strategy is evolving rapidly. FDA is developing frameworks for AAV immunogenicity assessment, re-administration protocols, and long-term safety monitoring. Navigating this evolving landscape requires a VP of Regulatory Affairs with deep gene therapy expertise.
Your regulatory affairs team should own FDA Type A, B, and C meeting preparation, briefing document development, and routine agency interaction. The CEO participates in the most strategic regulatory conversations: designation discussions, major guideline development comment opportunities, and any meeting where FDA leadership participation indicates a need for CEO-level engagement.
Rare Disease Community Engagement
Gene therapy programs often address rare diseases with organized, engaged patient and family communities. These communities can be powerful advocates for development programs, partners in clinical trial recruitment, and important voices in regulatory discussions.
Your CMO and a dedicated patient advocacy coordinator should own rare disease community relationships: attending patient conferences, building relationships with disease foundations, and ensuring patient community input is incorporated into development planning.
The CEO provides the visible organizational leadership at key moments: speaking at major patient community events, participating in natural history study advisory meetings, and representing the company when community relationships require executive-level trust-building.
Clinical Development Delegation in Gene Therapy
Gene therapy clinical trials have distinctive features: the need for long-term follow-up studies (sometimes up to 15 years for FDA requirements), the logistical challenges of treating patients at specialized academic centers, and the intensive safety monitoring requirements for novel modalities.
Your CMO and VP of Clinical Operations should own all clinical trial execution. The CEO reviews clinical program status in monthly leadership meetings and engages when program-level strategic decisions require CEO input.
For detailed guidance on clinical operations delegation, see our pharma clinical operations delegation guide.
Investor Communications
Gene therapy biotechs often have compelling scientific narratives and patient stories that create strong investor interest. Managing the investor narrative requires CEO involvement in communications strategy while delegating execution.
Your CFO and IR function prepare investor materials, coordinate conferences, and manage analyst relationships. You own the scientific narrative, maintain key investor relationships, and lead investor calls and major conferences.
Measuring Delegation Effectiveness
Track quarterly:
- CEO time in strategic/investor/BD work versus manufacturing/clinical operations
- Manufacturing batch success rates and timeline adherence
- Clinical milestone achievement rates
- Regulatory submission timelines
- Investor confidence indicators
- Partnership pipeline activity
Conclusion
Gene therapy biotech leadership sits at one of the most demanding intersections in medicine: unprecedented scientific potential, extreme manufacturing complexity, novel regulatory environment, and high patient community expectations. CEOs who are consumed by operational management cannot lead effectively across all of these dimensions.
The delegation framework described here builds the organizational infrastructure that allows gene therapy CEOs to direct their attention toward the strategic and external work that determines their company’s trajectory, while trusting expert teams to execute the technical work that advances their programs.
As McKinsey research on biotech leadership models has found, biotechs with strong functional leadership teams and clear CEO delegation structures significantly outperform those where the CEO maintains operational control. For gene therapy companies where the technical stakes are particularly high, this finding is especially relevant.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.